Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.

Ari NishimuraAkira OnoKazushige WakudaTakanori KawabataMichitoshi YabeTaichi MiyawakiEriko MiyawakiHiroaki KodamaNaoya NishiokaNobuaki MamesayaHaruki KobayashiShota OmoriHirotsugu KenmotsuTateaki NaitoHaruyasu MurakamiHideyuki HaradaToshiaki Takahashi

Published in: Investigational new drugs (2021)

Grade 2 or higher pneumonitis after durvalumab was not a prognostic factor of PFS in LA-NSCLC patients received durvalumab.

Keyphrases

prognostic factors
advanced non small cell lung cancer
end stage renal disease
epidermal growth factor receptor
small cell lung cancer
ejection fraction
chronic kidney disease
newly diagnosed
interstitial lung disease
peritoneal dialysis
brain metastases